journal
https://read.qxmd.com/read/36427512/prediction-of-autism-in-infants-progress-and-challenges
#1
REVIEW
Geraldine Dawson, Amber D Rieder, Mark H Johnson
Autism spectrum disorder (henceforth autism) is a neurodevelopmental condition that can be reliably diagnosed in children by age 18-24 months. Prospective longitudinal studies of infants aged 1 year and younger who are later diagnosed with autism are elucidating the early developmental course of autism and identifying ways of predicting autism before diagnosis is possible. Studies that use MRI, EEG, and near-infrared spectroscopy have identified differences in brain development in infants later diagnosed with autism compared with infants without autism...
November 22, 2022: Lancet Neurology
https://read.qxmd.com/read/36410374/time-to-reconsider-the-classification-of-multiple-sclerosis
#2
JOURNAL ARTICLE
Takashi Yamamura
No abstract text is available yet for this article.
November 18, 2022: Lancet Neurology
https://read.qxmd.com/read/36410373/multiple-sclerosis-progression-time-for-a-new-mechanism-driven-framework
#3
REVIEW
Tanja Kuhlmann, Marcello Moccia, Timothy Coetzee, Jeffrey A Cohen, Jorge Correale, Jennifer Graves, Ruth Ann Marrie, Xavier Montalban, V Wee Yong, Alan J Thompson, Daniel S Reich
Traditionally, multiple sclerosis has been categorised by distinct clinical descriptors-relapsing-remitting, secondary progressive, and primary progressive-for patient care, research, and regulatory approval of medications. Accumulating evidence suggests that the clinical course of multiple sclerosis is better considered as a continuum, with contributions from concurrent pathophysiological processes that vary across individuals and over time. The apparent evolution to a progressive course reflects a partial shift from predominantly localised acute injury to widespread inflammation and neurodegeneration, coupled with failure of compensatory mechanisms, such as neuroplasticity and remyelination...
November 18, 2022: Lancet Neurology
https://read.qxmd.com/read/36403581/credulity-of-exploratory-trials-for-cerebral-cavernous-malformations
#4
JOURNAL ARTICLE
Robert Shenkar, Issam A Awad
No abstract text is available yet for this article.
November 16, 2022: Lancet Neurology
https://read.qxmd.com/read/36403580/safety-and-efficacy-of-propranolol-for-treatment-of-familial-cerebral-cavernous-malformations-treat_ccm-a-randomised-open-label-blinded-endpoint-phase-2-pilot-trial
#5
JOURNAL ARTICLE
Silvia Lanfranconi, Elisa Scola, Jennifer M T A Meessen, Roberto Pallini, Giulio A Bertani, Rustam Al-Shahi Salman, Elisabetta Dejana, Roberto Latini
BACKGROUND: Observations in people with cerebral cavernous malformations, and in preclinical models of this disorder, suggest that the β-blocker propranolol might reduce the risk of intracerebral haemorrhage. We aimed to evaluate the safety and efficacy of prolonged treatment with propranolol to reduce the incidence of symptomatic intracerebral haemorrhage or focal neurological deficit in people with familial cerebral cavernous malformations. METHODS: We conducted a randomised, open-label, blinded-endpoint, phase 2 pilot trial (Treat_CCM) at six national reference centres for rare diseases in Italy...
November 16, 2022: Lancet Neurology
https://read.qxmd.com/read/36354027/tourette-syndrome-clinical-features-pathophysiology-and-treatment
#6
REVIEW
Kara A Johnson, Yulia Worbe, Kelly D Foote, Christopher R Butson, Aysegul Gunduz, Michael S Okun
Tourette syndrome is a chronic neurodevelopmental disorder characterised by motor and phonic tics that can substantially diminish the quality of life of affected individuals. Evaluating and treating Tourette syndrome is complex, in part due to the heterogeneity of symptoms and comorbidities between individuals. The underlying pathophysiology of Tourette syndrome is not fully understood, but recent research in the past 5 years has brought new insights into the genetic variations and the alterations in neurophysiology and brain networks contributing to its pathogenesis...
October 28, 2022: Lancet Neurology
https://read.qxmd.com/read/36354026/chronic-remote-ischaemic-conditioning-in-patients-with-symptomatic-intracranial-atherosclerotic-stenosis-the-rica-trial-a-multicentre-randomised-double-blind-sham-controlled-trial-in-china
#7
JOURNAL ARTICLE
Chengbei Hou, Jing Lan, Yinan Lin, Haiqing Song, Yuan Wang, Wenbo Zhao, Sijie Li, Ran Meng, Junwei Hao, Yuchuan Ding, Marc I Chimowitz, Marc Fisher, David C Hess, David S Liebeskind, Derek J Hausenloy, Jie Huang, Zhenguang Li, Xiujie Han, Jinbo Yang, Jin Zhou, Peimin Chen, Xinchen Zhu, Peilin Hu, Hongbo Pang, Wenwu Chen, Huisheng Chen, Guozhong Li, Dingbo Tao, Wei Yue, Zongen Gao, Xunming Ji
BACKGROUND: Intracranial atherosclerotic stenosis (ICAS) is one of the most common causes of stroke worldwide, and it is associated with a high risk of recurrent stroke with currently recommended treatments. We aimed to evaluate the effect of chronic remote ischaemic conditioning on prevention of ischaemic events in patients with symptomatic ICAS. METHODS: The RICA trial is a multicentre, randomised, double-blind, sham-controlled trial at 84 stroke centres in China...
October 27, 2022: Lancet Neurology
https://read.qxmd.com/read/36354025/remote-ischaemic-conditioning-for-stroke-prevention
#8
JOURNAL ARTICLE
Aravind Ganesh, Eric E Smith, Michael D Hill
No abstract text is available yet for this article.
October 27, 2022: Lancet Neurology
https://read.qxmd.com/read/36309041/intracerebral-haemorrhage-expansion-definitions-predictors-and-prevention
#9
REVIEW
Andrea Morotti, Gregoire Boulouis, Dar Dowlatshahi, Qi Li, Michel Shamy, Rustam Al-Shahi Salman, Jonathan Rosand, Charlotte Cordonnier, Joshua N Goldstein, Andreas Charidimou
Haematoma expansion affects a fifth of patients within 24 h of the onset of acute intracerebral haemorrhage and is associated with death and disability, which makes it an appealing therapeutic target. The time in which active intervention can be done is short as expansion occurs mostly within the first 3 h after onset. Baseline haemorrhage volume, antithrombotic treatment, and CT angiography spot signs are each associated with increased risk of haematoma expansion. Non-contrast CT features are promising predictors of haematoma expansion, but their potential contribution to current models is under investigation...
October 26, 2022: Lancet Neurology
https://read.qxmd.com/read/36272436/cop27-climate-change-conference-urgent-action-needed-for-africa-and-the-world
#10
JOURNAL ARTICLE
Lukoye Atwoli, Gregory E Erhabor, Aiah A Gbakima, Abraham Haileamlak, Jean-Marie Kayembe Ntumba, James Kigera, Laurie Laybourn-Langton, Robert Mash, Joy Muhia, Fhumulani Mavis Mulaudzi, David Ofori-Adjei, Friday Okonofua, Arash Rashidian, Maha El-Adawy, Siaka Sidibé, Abdelmadjid Snouber, James Tumwine, Mohammad Sahar Yassien, Paul Yonga, Lilia Zakhama, Chris Zielinski
No abstract text is available yet for this article.
October 18, 2022: Lancet Neurology
https://read.qxmd.com/read/36244364/safety-and-efficacy-of-risdiplam-in-patients-with-type-1-spinal-muscular-atrophy-firefish-part-2-secondary-analyses-from-an-open-label-trial
#11
JOURNAL ARTICLE
Riccardo Masson, Maria Mazurkiewicz-Bełdzińska, Kristy Rose, Laurent Servais, Hui Xiong, Edmar Zanoteli, Giovanni Baranello, Claudio Bruno, John W Day, Nicolas Deconinck, Andrea Klein, Eugenio Mercuri, Dmitry Vlodavets, Yi Wang, Angela Dodman, Muna El-Khairi, Ksenija Gorni, Birgit Jaber, Heidemarie Kletzl, Eleni Gaki, Paulo Fontoura, Basil T Darras
BACKGROUND: Risdiplam is an orally administered therapy that modifies pre-mRNA splicing of the survival of motor neuron 2 (SMN2) gene and is approved for the treatment of spinal muscular atrophy. The FIREFISH study is investigating the safety and efficacy of risdiplam in treated infants with type 1 spinal muscular atrophy versus historical controls. The primary endpoint of part 2 of the FIREFISH study showed that infants with type 1 spinal muscular atrophy attained the ability to sit without support for at least 5 s after 12 months of treatment...
October 13, 2022: Lancet Neurology
https://read.qxmd.com/read/36244363/new-results-for-risdiplam-in-spinal-muscular-atrophy
#12
JOURNAL ARTICLE
Susan T Iannaccone
No abstract text is available yet for this article.
October 13, 2022: Lancet Neurology
https://read.qxmd.com/read/36216016/correction-to-lancet-neurol-2022-published-online-sept-29-https-doi-org-10-1016-s1474-4422-22-00309-x
#13
(no author information available yet)
No abstract text is available yet for this article.
October 7, 2022: Lancet Neurology
https://read.qxmd.com/read/36216015/ageing-and-multiple-sclerosis
#14
REVIEW
Jennifer S Graves, Kristen M Krysko, Le H Hua, Martina Absinta, Robin J M Franklin, Benjamin M Segal
The factor that is most relevant and strongly associated with the clinical course of multiple sclerosis is chronological age. Very young patients exclusively have relapsing remitting disease, whereas those with later onset disease face a more rapid development of permanent disability. For people with progressive multiple sclerosis, the poor response to current disease modifying therapies might be related to ageing in the immune system and CNS. Ageing is also associated with increased risks of side-effects caused by some multiple sclerosis therapies...
October 7, 2022: Lancet Neurology
https://read.qxmd.com/read/36183712/traumatic-brain-injury-progress-and-challenges-in-prevention-clinical-care-and-research
#15
REVIEW
Andrew I R Maas, David K Menon, Geoffrey T Manley, Mathew Abrams, Cecilia Åkerlund, Nada Andelic, Marcel Aries, Tom Bashford, Michael J Bell, Yelena G Bodien, Benjamin L Brett, András Büki, Randall M Chesnut, Giuseppe Citerio, David Clark, Betony Clasby, D Jamie Cooper, Endre Czeiter, Marek Czosnyka, Kristen Dams-O'Connor, Véronique De Keyser, Ramon Diaz-Arrastia, Ari Ercole, Thomas A van Essen, Éanna Falvey, Adam R Ferguson, Anthony Figaji, Melinda Fitzgerald, Brandon Foreman, Dashiell Gantner, Guoyi Gao, Joseph Giacino, Benjamin Gravesteijn, Fabian Guiza, Deepak Gupta, Mark Gurnell, Juanita A Haagsma, Flora M Hammond, Gregory Hawryluk, Peter Hutchinson, Mathieu van der Jagt, Sonia Jain, Swati Jain, Ji-Yao Jiang, Hope Kent, Angelos Kolias, Erwin J O Kompanje, Fiona Lecky, Hester F Lingsma, Marc Maegele, Marek Majdan, Amy Markowitz, Michael McCrea, Geert Meyfroidt, Ana Mikolić, Stefania Mondello, Pratik Mukherjee, David Nelson, Lindsay D Nelson, Virginia Newcombe, David Okonkwo, Matej Orešič, Wilco Peul, Dana Pisică, Suzanne Polinder, Jennie Ponsford, Louis Puybasset, Rahul Raj, Chiara Robba, Cecilie Røe, Jonathan Rosand, Peter Schueler, David J Sharp, Peter Smielewski, Murray B Stein, Nicole von Steinbüchel, William Stewart, Ewout W Steyerberg, Nino Stocchetti, Nancy Temkin, Olli Tenovuo, Alice Theadom, Ilias Thomas, Abel Torres Espin, Alexis F Turgeon, Andreas Unterberg, Dominique Van Praag, Ernest van Veen, Jan Verheyden, Thijs Vande Vyvere, Kevin K W Wang, Eveline J A Wiegers, W Huw Williams, Lindsay Wilson, Stephen R Wisniewski, Alexander Younsi, John Yue, Esther L Yuh, Frederick A Zeiler, Marina Zeldovich, Roger Zemek
No abstract text is available yet for this article.
September 29, 2022: Lancet Neurology
https://read.qxmd.com/read/36183711/geoffrey-manley-tbi-guy
#16
JOURNAL ARTICLE
Adrian Burton
No abstract text is available yet for this article.
September 29, 2022: Lancet Neurology
https://read.qxmd.com/read/36179757/diagnosis-and-classification-of-optic-neuritis
#17
REVIEW
Axel Petzold, Clare L Fraser, Mathias Abegg, Raed Alroughani, Daniah Alshowaeir, Regina Alvarenga, Cécile Andris, Nasrin Asgari, Yael Barnett, Roberto Battistella, Raed Behbehani, Thomas Berger, Mukharram M Bikbov, Damien Biotti, Valerie Biousse, Antonella Boschi, Milan Brazdil, Andrei Brezhnev, Peter A Calabresi, Monique Cordonnier, Fiona Costello, Franz M Cruz, Leonardo Provetti Cunha, Smail Daoudi, Romain Deschamps, Jerome de Seze, Ricarda Diem, Masoud Etemadifar, Jose Flores-Rivera, Pedro Fonseca, Jette Frederiksen, Elliot Frohman, Teresa Frohman, Caroline Froment Tilikete, Kazuo Fujihara, Alberto Gálvez, Riadh Gouider, Fernando Gracia, Nikolaos Grigoriadis, José M Guajardo, Mario Habek, Marko Hawlina, Elena H Martínez-Lapiscina, Juzar Hooker, Jyh Yung Hor, William Howlett, Yumin Huang-Link, Zhannat Idrissova, Zsolt Illes, Jasna Jancic, Panitha Jindahra, Dimitrios Karussis, Emilia Kerty, Ho Jin Kim, Wolf Lagrèze, Letizia Leocani, Netta Levin, Petra Liskova, Yaou Liu, Youssoufa Maiga, Romain Marignier, Chris McGuigan, Dália Meira, Harold Merle, Mário L R Monteiro, Anand Moodley, Frederico Moura, Silvia Muñoz, Sharik Mustafa, Ichiro Nakashima, Susana Noval, Carlos Oehninger, Olufunmilola Ogun, Afekhide Omoti, Lekha Pandit, Friedemann Paul, Gema Rebolleda, Stephen Reddel, Konrad Rejdak, Robert Rejdak, Alfonso J Rodriguez-Morales, Marie-Bénédicte Rougier, Maria Jose Sa, Bernardo Sanchez-Dalmau, Deanna Saylor, Ismail Shatriah, Aksel Siva, Hadas Stiebel-Kalish, Gabriella Szatmary, Linh Ta, Silvia Tenembaum, Huy Tran, Yevgen Trufanov, Vincent van Pesch, An-Guor Wang, Mike P Wattjes, Ernest Willoughby, Magd Zakaria, Jasmin Zvornicanin, Laura Balcer, Gordon T Plant
There is no consensus regarding the classification of optic neuritis, and precise diagnostic criteria are not available. This reality means that the diagnosis of disorders that have optic neuritis as the first manifestation can be challenging. Accurate diagnosis of optic neuritis at presentation can facilitate the timely treatment of individuals with multiple sclerosis, neuromyelitis optica spectrum disorder, or myelin oligodendrocyte glycoprotein antibody-associated disease. Epidemiological data show that, cumulatively, optic neuritis is most frequently caused by many conditions other than multiple sclerosis...
September 27, 2022: Lancet Neurology
https://read.qxmd.com/read/36179756/bastiaan-bloem-power-against-parkinson-s-disease
#18
JOURNAL ARTICLE
Adrian Burton
No abstract text is available yet for this article.
September 27, 2022: Lancet Neurology
https://read.qxmd.com/read/36179755/a-new-classification-for-diagnosis-of-optic-neuritis
#19
JOURNAL ARTICLE
Steven L Galetta
No abstract text is available yet for this article.
September 27, 2022: Lancet Neurology
https://read.qxmd.com/read/36155663/val%C3%A3-rie-biousse-a-leader-in-neuro-ophthalmology
#20
JOURNAL ARTICLE
Udani Samarasekera
No abstract text is available yet for this article.
September 22, 2022: Lancet Neurology
journal
journal
20188
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.